Mark Hollywood

CIK: 0002104446

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ZYME

Zymeworks Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ZYME
Zymeworks Inc.
Jul 6, 2026
Award(A)
Direct
939 shares at avg. $22.22$21K
ZYME
Zymeworks Inc.
Jan 12, 2026
Exercise(M)
Direct
17.7K shares-
ZYME
Zymeworks Inc.
Jan 12, 2026
Sale(S)
Direct
6.1K shares at avg. $22.67$139K
ZYME
Zymeworks Inc.
Jan 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-
ZYME
Zymeworks Inc.
Jan 12, 2026
Award(A)
Restricted Stock Unit
Direct
47K shares-
ZYME
Zymeworks Inc.
Jan 12, 2026
Award(A)
Performance Stock Unit
Direct
66K shares-

		Type	Shares	Price		Ownership
Jul 6, 2026	ZYME Zymeworks Inc.	Award(A)	939	$22.22	$20,865	Direct
Jan 12, 2026	ZYME Zymeworks Inc.	Exercise(M)	17,666	-	$0	Direct
Jan 12, 2026	ZYME Zymeworks Inc.	Sale(S)	6,120	$22.67	$138,762	Direct
Jan 12, 2026	ZYME Zymeworks Inc.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct
Jan 12, 2026	ZYME Zymeworks Inc.	Award(A) Restricted Stock Unit	47,000	-	-	Direct
Jan 12, 2026	ZYME Zymeworks Inc.	Award(A) Performance Stock Unit	66,000	-	-	Direct

1-6 of 6 transactions

About Hollywood Mark

Hollywood Mark (SEC CIK 0002104446) files insider reports with the SEC as EVP & Chief Operating Officer of Zymeworks Inc. (ZYME).

Signal8 holds 3 ownership filings by Hollywood Mark (1 Form 3, 2 Form 4), filed between Jan 13, 2026 and Jul 6, 2026. Those filings report 6 transactions, from Jan 12, 2026 to Jul 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hollywood Mark's filings is in MIDDLETOWN, DE.

Recent filings by Hollywood Mark

Jul 6, 2026: Grant or award of ZYME shares (Form 4, code A).
Jan 12, 2026: Option exercise of ZYME shares (Form 4, code M).
Jan 12, 2026: Open-market sale of ZYME shares (Form 4, code S).
Jan 12, 2026: Grants or awards of ZYME derivative securities (3 lines, Form 4, code A).

Other insiders filing for Zymeworks Inc. (ZYME)

Schayowitz Adam, EVP, Head of R&D
Schneider Paul R, EVP, General Counsel
Platshon Scott, EVP, Chief Business Officer
Stafford Kristin, EVP, Chief Financial Officer
Mekan Sabeen, SVP & Chief Medical Officer
Cherry Brian N, Director

How to read Form 4 transaction codes